相关实验视频
Updated: Jan 8, 2026

09:01
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
8.4K
在患有腰部脑内出血的患者中服用预防性抗发作药物
Margaret Banker1, Juliana Silva Pinheiro do Nascimento2, Harish Shownkeen3
1Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Neurocritical care
|December 17, 2025
概括
预防性抗发作药物显著降低了脑内出血 (ICH) 后高风险患者的早期发作. 这种预防策略没有影响长期的功能结果.
科学领域:
- 神经学 神经学
- 神经外科 神经外科
- 临床药理学 临床药理学
背景情况:
- 早期发作是急性脑内出血 (ICH) 后的常见并发症.
- 患有ICH的患者,特别是患有叶叶血瘤的患者,面临着发作风险升高的风险.
- 确定ICH患者早期发作的有效预防策略对于改善患者的治疗结果至关重要.
研究的目的:
- 研究预防性抗发作药物与急性脑内出血 (ICH) 患者早期发作的发生率之间的关联.
- 评估早期发作预防在高风险ICH亚组中的有效性.
主要方法:
- 来自五个学术医疗中心 (2006-2023) 的前性观察队列的回顾性分析.
- 专注于300名患有自发性叶叶部ICH的患者,分析医生的裁量权下的抗发作药物管理.
- 使用调整后回归模型,使用包括年龄,血瘤体积和性别在内的共变量来评估发作的发生.
主要成果:
- 在14.3%的患者中,发生了早期发作.
- 接受预防性抗发作药物治疗的患者的早期发作发病率显著降低 (6.3%),与未接受预防 (21.6%) 患者相比.
- 在高风险患者中,预防性抗发作药物与早期发作的可能性降低有关 (调整后的几率比率为0.25,P = 0.0005),但对3个月的功能结果没有影响.
结论:
- 预防性抗发作药物与在脑内出血后风险较高的患者早期发作的发病率降低有关.
- 这些发现表明,在特定的ICH人群中,早期发作预防有潜在的益处.
- 可能需要进一步的前性研究来证实这些发现并建立最佳的预防方案.
相关概念视频
Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Antiepileptic Drugs: Calcium Channel Blockers
1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
603
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
603

